Skip to main content

Table 4 Risk predictors of OS in the univariate and multivariate analyses

From: Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Variable

Overall survival

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Age (≥55 years old vs < 55 years old)

1.247 (0.673–2.310)

0.483

  

AFPa (≥400ng/ml vs < 400 ng/ml)

1.858 (1.014–3.404)

0.045*

1.940 (1.008–3.735)

0.047*

Ascites (Have vs None)

2.15 (1.171–3.948)

0.014*

 

0.067

ECOG PSb (0–1 vs. 2)

2.414 (1.230–4.740)

0.008*

2.574 (1.278–5.185)

0.008*

Child-Pugh grade (A vs B)

2.114 (1.061–4.214)

0.033*

2.913 (1.385–6.123)

0.005*

Arterioportal fistula (Have vs None)

1.036 (0.555–1.931)

0.912

  

Hemihepatic HCCc (Yes vs. No)

0.454 (0.247–0.835)

0.011*

0.517 (0.269–0.992)

0.047*

HCCc diameter (>10cm vs. ≤ 10 cm)

1.454 (0.802–2.636)

0.218

  

Number of tumors (Single vs. Multiple)

0.327 (0.100–1.260)

0.065

  

Distant metastasis (Yes vs. No)

1.829 (0.955–3.502)

0.069

  

Hepatic vein tumor thrombosis (Yes vs. No)

1.844 (0.850–4.003)

0.122

  

Cavernous transformation collateral (Yes vs. No)

0.703 (0.387–1.275)

0.246

  

PVTTd type (III vs. IV)

0.801 (0.371–1.731)

0.573

  
  1. *P < 0.05
  2. aAFP alpha fetoprotein
  3. bECOG PS Cooperative Oncology Group performance status
  4. cHCC hepatocellular carcinoma
  5. dPVTT portal vein tumor thrombosis